Supporters of therapy as a cause of DID suggest that a small number of clinicians diagnosing a disproportionate number of cases would provide evidence for their position though it has also been claimed that higher rates of diagnosis in specific countries like the United States may be due to greater awareness of DID. Lower rates in other countries may be due to artificially low recognition of the diagnosis. However, false memory syndrome per se is not regarded by mental health experts as a valid diagnosis, and has been described as "a non-psychological term originated by a private foundation whose stated purpose is to support accused parents," and critics argue that the concept has no empirical support, and further describe the False Memory Syndrome Foundation as an advocacy group that has distorted and misrepresented memory research. Children
The rarity of DID diagnosis in children is cited as a reason to doubt the validity of DID, and proponents of both etiologies believe that the discovery of DID in a child who had never undergone treatment would critically undermine the SCM. Conversely, if children are found to develop DID only after undergoing treatment it would challenge the traumagenic model. As of 2011, approximately 250 cases of DID in children have been identified, though the data does not offer unequivocal support for either theory.
The mechanism of action of timolol is probably the reduction of the formation of aqueous humor in the ciliary body in the eye. It was the first beta blocker approved for topical use in treatment of glaucoma in the United States (1978). When used by itself, it depresses intraocular pressure (IOP) 18–34% below baseline within first few treatments. However, there are short-term escape and long-term drift effects in some people. That is, tolerance develops. It may reduce the extent of the diurnal IOP curve up to 50%. The IOP is higher during sleep. Efficacy of timolol in lowering IOP during the sleep period may be limited. It is a 5–10× more potent β-blocker than propranolol. Timolol is light-sensitive; it is usually preserved with 0.01% benzalkonium chloride (BAC), but also comes BAC-free. It can also be used in combination with pilocarpine, carbonic anhydrase inhibitors or prostaglandin analogs.A Cochrane review compared the effect of timolol versus brimonidine in slowing the progression of open angle glaucoma in adults but found insufficient evidence to come to conclusions. On the skin
In its gel form it is used on the skin to treat infantile hemangiomas. Contraindications
The medication should not be taken by individuals with:
An allergy to timolol or any other beta-blockers
Asthma or severe chronic obstructive bronchitis
A slow heart rate (bradycardia), or a heart block
Heart failure

Side effects
The most serious possible side effects include cardiac arrhythmias and severe bronchospasms.